DEM Biopharma, Inc.

DEM Biopharma, Inc.

Biotechnology Research

Cambridge, Massachusetts 1,580 followers

Pioneering the next-generation of macrophage immunotherapies

Über uns

DEM Bio is pioneering the next generation of immunotherapeutics that unleash macrophages and immune phagocytes to eliminate tumors by targeting ‘Don’t eat me’ (DEM) and ‘Eat me’ (EM) signals on cancer cells and macrophages. Founded by Longwood Fund and is supported by a syndicate of biotech investors and headquartered in Boston, MA.

Website
https://dembiopharma.com/
Industrie
Biotechnology Research
Größe des Unternehmens
11-50 Mitarbeiter
Hauptsitz
Cambridge, Massachusetts
Typ
In Privatbesitz
Gegründet
2022

Standorte

Employees at DEM Biopharma, Inc.

Aktualisierungen

Ähnliche Seiten

Jobs durchsuchen

Finanzierung